SCHEMBL15076008

SCHEMBL15076008

CC(C)(C)OC(=O)Cn1ccc2ccccc2c1=O

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.63
TNF P01375 1/20 0.53
ALDH1A1 P00352 3/20 0.49
MAPT P10636 3/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
PSMB1 P20618 1/20 0.48
PSMB5 P28074 1/20 0.48
NLRP3 Q96P20 1/20 0.48
KMT2A Q03164 3/20 0.47
LMNA P02545 2/20 0.47
RXFP1 Q9HBX9 2/20 0.46
MEN1 O00255 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
USP2 O75604 1/20 0.46
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31445308 0.84 KDM4E (0.76) KDM4ETNFALDH1A1MAPTPSMB1
SCHEMBL30220138 0.82 ALDH1A1 (0.45) KDM4ETNFALDH1A1PSMB1PSMB5
SCHEMBL31618416 0.82 KDM4E (0.44) KDM4ETNFALDH1A1RAB9A
SCHEMBL3597779 0.81 KMT2A (0.59) KDM4EALDH1A1SMN1; SMN2KMT2ALMNA
SCHEMBL30229742 0.81 KMT2A (0.59) KDM4EALDH1A1SMN1; SMN2KMT2ALMNA
SCHEMBL17577713 0.78 KDM4E (0.56) KDM4ETNFALDH1A1MAPTSMN1; SMN2
SCHEMBL1757681 0.77 KDM4E (0.55) KDM4ETNFALDH1A1MAPTSMN1; SMN2
SCHEMBL10203523 0.77 KMT2A (0.62) KDM4ETNFALDH1A1MAPTSMN1; SMN2
SCHEMBL23909115 0.77 KDM4E (0.41) KDM4ETNFALDH1A1MAPTPSMB1
SCHEMBL1687421 0.76 KDM4E (0.57) KDM4ETNFALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9688702-B2 Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors ARES TRADING (CH) 2017-06-27 US disclosed
US-9688702-B2 Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors ARES TRADING (CH) 2017-06-27 US disclosed
US-20140364396-A1 Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors ARES TRADING SA (CH) 2014-12-11 US disclosed
US-20140364396-A1 Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors ARES TRADING SA (CH) 2014-12-11 US disclosed
WO-2013092979-A1 ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS ARES TRADING S.A. (CH) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364396-A1 Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors PSMB7, PSMA7, PSMB1 KDM4E 1318/4885TNF 997/4885ALDH1A1 2975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.